Glycorex Transplantation (GTAB B): Signs agreement with distributor in Romania
Glycorex Transplantation AB (publ) announces that the company has signed an agreement with a Romanian distributor for its product, Glycosorb® ABO.
As part of its market expansion strategy, the company has signed an agreement today with Renamed Farma in Romania. Founded in 1994, the company specializes in medical equipment with a focus on areas such as hemodialysis and apheresis. It employs 40 staff members, including doctors and engineers. Therefore, Glycosorb® ABO is a suitable addition to their existing product portfolio and customer network.
In recent years, the number of kidney transplants from living donors in Romania has increased. In 2022, there were 230 kidney transplants, out of which over 30% were from living donors, putting the market on par with that of Denmark.
For more information, please contact:
Johan Nilsson, interim CEO
Email: johan.nilsson@glycorex.com,Tel: +46 46 286 5230
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood. The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 25 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. Product development and production takes place in the company's own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,000 transplants in over 25 countries. In addition to Europe, Glycosorb® ABO is used in Australia, Canada, India, Israel, Mexico, Singapore, South Africa, and Thailand, for example.
The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.